These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36657359)

  • 1. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
    Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
    Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures.
    Hixson J; Gidal B; Pikalov A; Zhang Y; Mehta D; Blum D; Cantu D; Grinnell T;
    Epilepsy Res; 2021 Mar; 171():106561. PubMed ID: 33556737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
    Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
    Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
    Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
    Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
    Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
    Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
    Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
    Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
    Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
    CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
    Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
    Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
    Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
    Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
    Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
    Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.
    Costa R; Steinhoff B; Gama H; Ikedo F; Rocha JF; Soares-da-Silva P
    Drugs Aging; 2018 Dec; 35(12):1109-1117. PubMed ID: 30387043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
    Lattanzi S; Trinka E; Zaccara G; Striano P; Russo E; Del Giovane C; Silvestrini M; Brigo F
    Drugs; 2022 Feb; 82(2):199-218. PubMed ID: 35061214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses.
    Mehta D; Davis M; Epstein AJ; Wensel B; Grinnell T; Williams GR
    Neurol Ther; 2020 Dec; 9(2):585-598. PubMed ID: 32949379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
    Lee SK; Lee SA; Hong SB; Cho YW; Castilla-Fernández G; Fonseca MM; Moreira J; Gama H; Holenz J
    Clin Transl Sci; 2024 May; 17(5):e13802. PubMed ID: 38787305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
    Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
    Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.
    Altalib H; Grinnell T; Cantu D; Ikedo F; Vieira M; Zhang Y; Blum D
    Epilepsia Open; 2022 Dec; 7(4):616-632. PubMed ID: 35908275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and tolerability of adjunctive eslicarbazepine acetate in patients with focal to bilateral tonic-clonic seizures.
    Chung S; Guirguis S; Cantu D; Moreira J; Magalhães LM; Hall D; Grinnell T
    Epilepsy Res; 2024 Feb; 200():107285. PubMed ID: 38183687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
    Brandt C; Dimova S; Elmoufti S; Laloyaux C; Nondonfaz X; Klein P
    Epilepsy Behav; 2023 Jan; 138():108967. PubMed ID: 36435010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
    Ryvlin P; Dimova S; Elmoufti S; Floricel F; Laloyaux C; Nondonfaz X; Biton V
    Epilepsia; 2022 Aug; 63(8):2024-2036. PubMed ID: 35582748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.